Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin versus placebo for prevention of contrast-induced nephropathy in primary angioplasty
IRCT20120215009014N539Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in contrast-induced nephropathy (CIN) comparing Melatonin plus routine treatment with Placebo plus routine treatment (2 arms). Primary endpoints: Plasma creatinine level, Blood urea nitrogen plasma level and 1 more. Started Nov 2024; status: completed.
02
Drugs
melatonin
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on IRCT20120215009014N539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N539.